ロード中...
Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
BACKGROUND: Rituximab and trastuzumab were the first therapeutic monoclonal antibodies (mAbs) approved in oncology. Both antibodies are delivered by the intravenous (IV) route, but recently subcutaneous (SC) formulations have been developed. Subcutaneous administration of mAbs can offer substantial...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3776971/ https://ncbi.nlm.nih.gov/pubmed/24002601 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.371 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|